IVD Technology Magazine announces the Evolution of Advanced IVDs Conference on September 19-20, 2012 at the San Diego Convention Center. This one-of-a-kind event addresses all the key regulatory, business and technical challenges of the niche IVD industry. "The IVD sector is under more systemic pressure than ever. The industry's ability to understand, innovate and market to key clinical needs will determine the success with which our industry can re-assert, and be recognized for, its immense value to the global healthcare system," states Jon Vance of MedDx Capital Advisors, advisory board member and speaker at the inaugural event. Jon will be leading a panel discussion on the recent trends in capital markets and how to determine the best funding strategy for an IVD startup. Other panelists include Peter Klemm, CEO at Applied Proteomics and Marty Waters, Partner at Wilson Sonsini.
The comprehensive two-day program promises to serve as an ideal setting for major players, IVD entrepreneurs and industry experts to network face-to-face and discuss timely and effective practical strategies and solutions for IVD companies. The agenda includes segments on regulatory landscape, commercialization and growth opportunities, latest developments in IVD technology, and a special feature on companion diagnostics.
Opening the regulatory segment, Don St.Pierre, Deputy Director for New Product Evaluation in the Office of In Vitro Diagnostics at the FDA will be remotely presenting on submissions in 510(k), PMA, and de novo classifications as well as addressing concerns for longer review times and guidance documents. In the technology segment, presentations on the latest in sequencing, molecular diagnostics, assays and point of care devices will be delivered by top speakers from Amgen, Roche, Gen-Probe, Ambry Genetics, and Alere.